These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15160951)

  • 1. Treatment of multiple myeloma with all-trans retinoic acid alone and in combination with chemotherapy: a phase I/II trial.
    Koskela K; Pelliniemi TT; Pulkki K; Remes K
    Leuk Lymphoma; 2004 Apr; 45(4):749-54. PubMed ID: 15160951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma.
    Niesvizky R; Siegel DS; Busquets X; Nichols G; Muindi J; Warrell RP; Michaeli J
    Br J Haematol; 1995 Jan; 89(1):217-8. PubMed ID: 7833269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction.
    Ogata A; Nishimoto N; Shima Y; Yoshizaki K; Kishimoto T
    Blood; 1994 Nov; 84(9):3040-6. PubMed ID: 7949175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
    Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
    Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of all-trans retinoic acid (ATRA) on human myeloma cells.
    Otsuki T; Sakaguchi H; Hatayama T; Wu P; Takata A; Hyodoh F
    Leuk Lymphoma; 2003 Oct; 44(10):1651-6. PubMed ID: 14692515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
    Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
    Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High, intermittent dose of all-trans retinoic acid in combination with alpha-interferon for advanced multiple myeloma.
    Juturi J; Bukowski RA; Bocock K; Bloom T; Finke J; Hussein MA
    Haematologica; 2001 Jul; 86(7):776-7. PubMed ID: 11454541
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1).
    Chen YH; Lavelle D; DeSimone J; Uddin S; Platanias LC; Hankewych M
    Blood; 1999 Jul; 94(1):251-9. PubMed ID: 10381520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line, U266B1.
    Okamura T; Masuda M; Arai Y; Ishida C; Shudou K; Mizoguchi H
    Exp Hematol; 1998 Jun; 26(6):501-6. PubMed ID: 9620283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of all-trans retinoic acid and interferon-gamma upregulated p27(kip1) and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells.
    Zhang R; Banik NL; Ray SK
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):407-16. PubMed ID: 17960384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purging of myeloma cells using all-trans retinoic acid in a mouse model.
    Henry JM; Morley AA; Sykes PJ
    Exp Hematol; 2001 Mar; 29(3):315-21. PubMed ID: 11274759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.
    Musto P; Sajeva MR; Sanpaolo G; D'Arena G; Scalzulli PR; Carotenuto M
    Haematologica; 1997; 82(3):354-6. PubMed ID: 9234591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dexamethasone, all-trans retinoic acid, vitamin D(3) and interferon-alpha on FO myeloma cells.
    Ozdemir F; Esen N; Ovali E; Tekelioglu Y; Yilmaz M; Aydin F; Kavgaci H; Boruban C
    Chemotherapy; 2004 Oct; 50(4):190-3. PubMed ID: 15347912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells.
    Otsuki T; Yata K; Sakaguchi H; Kurebayashi J; Matsuo Y; Uno M; Fujii T; Eda S; Isozaki Y; Yawata Y; Yamada O; Wada H; Sugihara T; Ueki A
    Br J Haematol; 2002 Mar; 116(4):787-95. PubMed ID: 11886382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.
    Hönemann D; Chatterjee M; Savino R; Bommert K; Burger R; Gramatzki M; Dörken B; Bargou RC
    Int J Cancer; 2001 Sep; 93(5):674-80. PubMed ID: 11477577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
    Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
    Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of myeloma cell growth by all-trans retinoic acid is associated with upregulation of p21WAF1 and dephosphorylation of the retinoblastoma protein.
    Lavelle D; Chen YH; Hankewych M; Desimone J
    Leuk Lymphoma; 1999 Oct; 35(3-4):261-8. PubMed ID: 10706449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.